European Heart Rhythm Association Summit

Research in Arrhythmias: Institutions, Industry and Networking needs

Silvia G Priori



Clinical research: what do we need in EP

- Clinical research in our area is mainly conducted with large international clinical trials (mainly planned and conducted in the USA) and research at individual centers.
- Less attention is paid to the collection of solid epidemiological data and surveys.



Surveys, Registries, Data bases, Clinical Observatories....


Why do we need them at the time of clinical mega-trials?



The gaps of the trials

- Patients enrolled in clinical trials are:
- limited in numbers
- selected to ensure compliance to protocol
- better treated
- followed at tertiary centers
- DATA FROM REAL LIFE ARE IMPORTANT








Epidemiological data in Europe

- We lack epidemiological data in Europe
- In the context of the preparation of Guidelines on prevention of SCD the writing committee realized that there are no solid figures of the incidence of SCD in Europe.
- National data are not collected in a uniform way to allow easy pooling.



Epidemiological data

• CAT Trial designed on assumption of mortality of 30% at first year. Mortality was 5% at first year!





Clinical trials/ Registries/Data bases/Clinical Observatories

- Test the results of trials in the unselected population of clinical practice.
- Broad geographic distribution
- Representation of medical centers
- More realistic compliance to therapy and followup



The infrasructure for networking

 In Europe thanks to the strenght of established Societies and WG in EP there is already a capillary infrastructure that can develop EUROPEAN sinergies for research.



WHAT EHRA CAN DO

- EHRA can promote sinergies among EP societies and WGs to gather resources to merge national Registries and Observatories.
- EHRA members can act at the national level to encourage the creation of local data bases and observatories that can be joined to provide a european view.

EUROPEAN Heart Rhythim ASSOCIATION

Implementation of Guidelines

- Projects like the Euro Heart Survey provide a structure to monitor at the European level adherence of practice to clinical guidelines.
- EHRA can facilitate networking to develop this type of activities.



Hurdles to Clinical Research

- Lack of attractiveness for the professional figure of the physician-scientist
- Tighter control of health-care resources has limited the opening of positions for academic medicine
- Progressive reduction of European Funding for research
- Increasing cost of clinical research and of clinical trials



Hurdles to Clinical Research: the financial aspect

- Lack or paucity of financial support for investigating topics unrelated to drug / device development
- Lack of resources for creating registries to collect data with uniform methodology on unselected & consecutive patients in different European countries.



Translational research

- The commitment of EHRA in promoting research should include promotion of BASIC SCIENCE.
 - Education
 - Promote the figure of the MD/PhD in EP
 - Facilitate and encourage interaction with the Basic EP community (WG cellular EP)
 - Develop a training program (fellowship) for clinician/scientists



What EHRA is doing

- EHRA has the largest training fellowship program of the ESC (larger than that of the ESC itself)
- 42 applications for EP fellowships for 10 awards (5 basic training 5 advanced training)
- 14 applications for EP training centers
- Promote international exchange, crossfertilization, collaboration environment.



WHAT EHRA CAN DO

- Promote programs to support training of research scientists.
- Give credibility and value to the professional profile of the research scientist.

 Promote the development of professional incentives/ recognition for clinicians with a reserach training.



Industry: a most important partner for the medical community

 Development of new therapeutic agents / devices and diagnostic procedures is based on the interaction between science and technology and can only be achieved by an interaction between the academia and the industry.



Industry: a most important partner for the medical community

- R&D groups within the industry are abandoning Europe and concentrating in the USA: this is a negative trend that is market-driven and should be attenuated by creating incentives for maintaining R&D activities in Europe.
- EHRA can play and important role in requesting involvement of European in EP in R&D initiatives.



The need for funding independent research

- If clinical trials are organized predominantly by the industry, the medical community has to face several dilemmas:
 - The study design may be planned to achieve selected objectives i.e. maximize the probability of positive outcomes
 - Positive trials are unlikely to be repeated
 - The selection of the study population may be targeted to cost containment



The example of women enrollment in cardiovascular trials

- Because the base-line rate of cardiovascular disease is so much lower in women than in men 40,000 women had to enter the Women's Health Study versus 22,000 men in the Physicians' Health Study to test a very similar hypothesis
- Obviously this means that it is more expensive to conduct a trial in cardiovascular medicine including women with a lower event rate.



The need for independent trials

- EHRA can play an important role in promoting the need for independent trials that allow to address issues that are not of interest to the Industry.
- EHRA should act at European level to promote funds for clinical trials in EP



Conclusions

- EHRA THROUGH NATIONAL SOCEITIES AND WORKING GROUPS IN EP CAN:
- Support the development of networks for clinical trials/ observatories/registries/surveys in Europe
- Promote education on science, clinical research and translational research by creating programs that encourage young doctors to engage in research.
- Increase the interaction between basic scientists and clinicians in order to maximize the application of novel developments into the clinical arena
- Attract the Industry to invest in translational research in Europe

